Search results
Results from the WOW.Com Content Network
In June, Abbvie acquired TeneoOne and its lead compound TNB-383B. The compound is a BCMA-targeting immunotherapeutic for relapsed or refractory multiple myeloma. [31] In March 2022, AbbVie acquired Syndesi Therapeutics for up to $1 billion and its portfolio of novel modulators of the synaptic vesicle protein 2A and lead compound SDI-118.
For some Abbott Labs shareholders, the new year brought with it a new company called AbbVie. Formerly Abbott's branded pharmaceuticals business, shares of the new stock were distributed to ...
And since it split from Abbott in 2013, AbbVie has increased its dividend by 310%. The stock's forward yield is now around 3.8%, compared to the S&P 500's average of 1.3%. So despite its recent ...
When Abbott split off its pharmaceuticals division, Abbvie, in 2013, the Ensure product line remained with Abbott along with other nutritional products. [ 8 ] As of 2016, variants of Ensure included: [ 9 ]
AbbVie will inherit all of Abbott's brand pharmaceutical and biologic products, while the new Abbott will keep branded generics, diagnostics, medical devices, and nutrition lines of business.
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, in the United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products.
Technically, Abbott Labs has been around for decades. But the new Abbott Laboratories stock -- the one that no longer contains the drug division spun off as AbbVie -- has existed for only six months.
Abbott Labs' (NYS: ABT) upcoming spinoff company, AbbVie, is forefront on investors' minds at the moment, as it means the core company will lose its blockbuster drug Humira over to AbbVie. In this ...